SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid discussions around market downturns, potential support levels, and the influence of macroeconomic factors. Community members are debating whether this is a buying opportunity or the start of a deeper correction, while also considering the impact of potential government actions and large liquidations. Some traders are pointing to technical indicators and historical patterns to predict future price movements.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as community members discuss its potential to be the next PEPE, with many highlighting its availability on the Solana blockchain via Phantom Wallet. The coin is experiencing increased attention and bullish sentiment, with some suggesting it's gearing up for a significant breakout.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

The stock is trending as investors digest a newly announced AI hosting agreement with Fluidstack, backed by Google, and an $800 million convertible note offering. While some view the deal as a major win with long-term potential in the AI data center space, others are concerned about potential dilution from the convertible notes. Community discussions revolve around the details of the deal, potential for future growth, and whether the recent price drop is a buying opportunity or a sign of further declines.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending due to increased community interest following a recent mention on Jim Cramer's Mad Money, highlighting potential FDA approval of their epinephrine sublingual film, Anaphylm. The community is actively discussing the positive implications of the Cramer mention, the potential for a squeeze, and the possible competitive advantages over existing treatments like EpiPen and Neffy. Some caution against the Cramer effect while others celebrate the increased awareness for AQST.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Fueled by positive clinical trial results for its oral acromegaly treatment, CRNX is trending as traders discuss the potential for a short squeeze given high short interest and substantial institutional ownership. The community is closely watching for the offering to close and debating its impact on the stock's price action, with some anticipating a continued rise while others foresee a pullback. Bullish sentiment is supported by analysts' optimistic revenue projections, while bears point to the company's financials and insider selling.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as discussions revolve around rare earth elements and potential price floors being considered by G7 nations to counter China's dominance in the sector. Community members are weighing the potential impacts of government stakes and contracts, drawing comparisons to Lithium Americas, while also speculating on future price targets. Investors are closely monitoring technical indicators and upcoming catalysts, such as earnings and processing capacity increases.

$JINGLE  is a meme community on Solana, The project was fair-launched on Pump.fun, This is a purely community-driven project.  $JINGLE a community powered token celebrating global holidays!  With a dedicated team and a vibrant community, $JINGLE Token aims to bring joy and prosperity to holders while embodying the spirit of the internet's favorite amphibian. Jump on board and let's make waves in the crypto pond together!

Jingle

JINGLE.X is trending as community members are actively discussing potential gains and encouraging others to buy, with some mentioning a possible pump. Several are drawing comparisons to other meme coins and touting it as the next opportunity for significant returns. The conversation also includes promotion of related Solana-based tokens, creating a broader buzz within that ecosystem.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas Corp ($LAC) is trending due to speculation around a potential equity stake from the US government, linked to a loan renegotiation for the Thacker Pass lithium project. The community is buzzing about the potential for a short squeeze and comparing it to past government investments in companies like MP Materials. Some traders are setting price targets, while others remain cautious, citing concerns about dilution and the company's financials.

Concentrix Corp. engages in the provision of customer experience solutions and technology. The company was founded in 1973 and is headquartered in Newark, CA.

Concentrix Corp.

Concentrix Corporation

Concentrix (CNXC) is trending following an earnings report that included lowered guidance, which has sparked debate among investors regarding a potential overdone sell-off. Community members are weighing whether the stock will rebound or test lower support levels, while also noting a significant short interest that could lead to a squeeze. Despite the negative reaction, some are pointing to the company's low PE ratio as a reason for optimism.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as its community rallies behind the coin, expressing bullish sentiment and encouraging others to join. Many allude to support from notable investors and highlight the strength of the community-driven movement. The coin is associated with the popular Rage Guy meme, potentially contributing to its appeal within the crypto space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrops has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied 18% on Wednesday morning at the time of writing.&nbsp;Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome. &nbsp;In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250917093826/en/Vyome-Presents-Strong-Data-Showing-Topical-VT-1908-is-an-Effective-Treatment-for-Uveitis-Opening-Up-a-%243B-Addressable-Market-Opportunity">stated</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIND">HIND stock</a> jumped from ‘neutral’ to ‘extremely bullish territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels. Shares of the company traded as high as 70% in the pre-market session.&nbsp;According to Vyome, steroids are the first line of treatment for uveitis, but many patients do not respond to them, and they also cause major complications. “There is a huge unmet need for a topically administered drug to replace steroid use in the eye. Vyome is developing VT-1908 to address this major unmet need,” the company said while adding that the broader addressable global market to treat inflammation in the eye is expected to exceed $20 billion by 2030.“We are excited with the preclinical efficacy signals. We expect to initiate Phase 1/2 clinical trial in the second half of 2026,” CEO Venkat Nelabhotla said. While the company will initially target uveitis, the long-term goal is to replace steroids to treat ocular inflammation, he said.HIND stock is down by 98% this year and by about 99% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-its-obesity-pill-topped-novo-nordisks-oral-drug-in-late-stage-diabetes-trial/chDGpSDRd6X">Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

HIND Stock Rallies 70% Pre-Market Today – Find Out Why

In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said. 

Equity

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. The company was founded on January 2, 2008 and is headquartered in San Clemente, CA.

Vyome Holdings Inc.

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

HIND
Vyome Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HIND News

HIND Vyome Holdings Inc.